secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-07-11T23:59:59+00:00
Accession:  0001558370-24-009750
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path provides clinical update; expands prexigebersen into obesity preclinical studies
--------------------------------------------------------------------------------

- Phase 2 AML trial paused for interim analysis; expects to complete enrollment in cohorts 1&2 over 18 months.
- Phase 1/1b BP1001-A advanced to dose level 2; expects dose level 3 by year-end.
- Phase 1/1b BP1002 completed second dose cohort (40 mg/m2); advancing to dose level 3 in Q4 2024.
- Developed molecular biomarkers for prexigebersen; preparing preclinical obesity studies.
- Phase 1 BP1002 in lymphoma/CLL enrolling second dose cohort; results expected year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024009750/0001558370-24-009750-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024009750/bpth-20240708x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009750

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer